TOLBUTAMIDE: 33 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
33
Total FAERS Reports
1 (3.0%)
Deaths Reported
20
Hospitalizations
33
As Primary/Secondary Suspect
7
Life-Threatening
Approved Prior to Jan 1, 1982
FDA Approved
Discontinued
Status
Yes
Generic Available
FDA Application: 010670 ·
First Report: 2007 · Latest Report: 20161120
What Are the Most Common TOLBUTAMIDE Side Effects?
#1 Most Reported
Renal failure acute
10 reports (30.3%)
#2 Most Reported
International normalised ratio increased
10 reports (30.3%)
#3 Most Reported
Hypoglycaemia
10 reports (30.3%)
All TOLBUTAMIDE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Epistaxis | 10 | 30.3% | 0 | 10 |
| Hypoglycaemia | 10 | 30.3% | 0 | 10 |
| International normalised ratio increased | 10 | 30.3% | 0 | 10 |
| Renal failure acute | 10 | 30.3% | 0 | 10 |
| Fatigue | 8 | 24.2% | 0 | 7 |
| Blood glucose increased | 7 | 21.2% | 0 | 7 |
| Crying | 7 | 21.2% | 0 | 7 |
| Feeling cold | 7 | 21.2% | 0 | 7 |
| Hypersomnia | 7 | 21.2% | 0 | 7 |
| Injection site pruritus | 7 | 21.2% | 0 | 7 |
| Liver disorder | 7 | 21.2% | 0 | 7 |
| Nausea | 7 | 21.2% | 0 | 7 |
| Suicidal ideation | 7 | 21.2% | 0 | 7 |
| Thinking abnormal | 7 | 21.2% | 0 | 7 |
| Hyponatraemia | 6 | 18.2% | 0 | 0 |
| Delirium | 5 | 15.2% | 0 | 0 |
Who Reports TOLBUTAMIDE Side Effects? Age & Gender Data
Gender: 81.0% female, 19.0% male. Average age: 74.4 years. Most reports from: NL. View detailed demographics →
Is TOLBUTAMIDE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2007 | 1 | 1 | 1 |
| 2013 | 7 | 0 | 7 |
| 2015 | 1 | 0 | 0 |
| 2016 | 1 | 0 | 1 |
What Is TOLBUTAMIDE Used For?
| Indication | Reports |
|---|---|
| Type 2 diabetes mellitus | 16 |
| Product used for unknown indication | 11 |
Official FDA Label for TOLBUTAMIDE
Official prescribing information from the FDA-approved drug label.